Search Results - A. R. Babaeva

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    Experience with tofacitinib in the treatment of resistant rheumatoid arthritis

    Experience with tofacitinib in the treatment of resistant rheumatoid arthritis by A. R. Babaeva, E. V. Kalinina, D. E. Karateev

    Published 2015-06-01

    The Russian Federation has not got sufficient experience with tofacitinib (TOFA) in patients with rheumatoid arthritis (RA) so far; in this connection, all follow-ups using this drug in real clinical practice are of particular interest.Objective: to evaluate the efficancy and safety of TOFA in an op...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    AMLODIPINE IN CORRECTION OF HIGH RISK ARTERIAL HYPERTENSION: FOCUS ON MECHANISMS OF INFLAMMATION

    AMLODIPINE IN CORRECTION OF HIGH RISK ARTERIAL HYPERTENSION: FOCUS ON MECHANISMS OF INFLAMMATION by A. A. Tarasov, S. I. Davydov, T. A. Bezborodova, M. A. Gordeeva, A. R. Babaeva

    Published 2016-01-01

    Aim. To study the effect of amlodipine on the main indicators of systemic inflammation and its safety in patients with arterial hypertension (HT) in combination with ischemic heart disease (IHD) or diabetes mellitus (DM) type 2. Material and methods. Patients with HT (2-3 degree) associated with IHD...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    TRIMETAZIDINE MB ROLE IN THE OPTIMISATION OF THE ACUTE CORONARY SYNDROME TREATMENT: EFFECTS ON ENDOTHELIAL DYSFUNCTION AND SYSTEMIC INFLAMMATION

    TRIMETAZIDINE MB ROLE IN THE OPTIMISATION OF THE ACUTE CORONARY SYNDROME TREATMENT: EFFECTS ON ENDOTHELIAL DYSFUNCTION AND SYSTEMIC INFLAMMATION by S. I. Davydov, V. V. Titova, M. A. Gordeeva, A. A. Tarasov, A. R. Babaeva

    Published 2013-12-01

    Aim. To study the effects of trimetazidine MB therapy on the clinical manifestations and markers of endothelial dysfunction and systemic inflammation in patients with acute coronary syndrome (ACS). Material and methods. This open, comparative, randomised parallel-group study included 60 patients wit...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  4. 4
    OPYT PRIMENENIYa NOVOGO OTEChESTVENNOGO PREPARATA ANTITsITOKINOVOGO DEYSTVIYa V KOMBINIROVANNOM LEChENII REVMATOIDNOGO ARTRITA

    OPYT PRIMENENIYa NOVOGO OTEChESTVENNOGO PREPARATA ANTITsITOKINOVOGO DEYSTVIYa V KOMBINIROVANNOM LEChENII REVMATOIDNOGO ARTRITA by A R Babaeva, E V Cherevkova, V I Petrov, M V Kachanova, S A Sergeeva

    Published 2005-06-01 Get full text
    Article

    Save to List
    Saved in:
  5. 5
    New perspectives in immunological diagnostics of coronary heart disease

    New perspectives in immunological diagnostics of coronary heart disease by S. I. Davydov, A. A. Tarasov, A. L. Emelyanova, M. A. Kiseleva, A. R. Babaeva

    Published 2012-02-01

    Aim. To assess the diagnostic value of immunological markers of endothelial dysfunction (ED) in various clinical variants of coronary heart disease (CHD). Material and methods. The study included 455 patients with various clinical variants of CHD. The control group (CG) included 70 individuals witho...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  6. 6
    Diagnosis of acute rheumatic fever

    Diagnosis of acute rheumatic fever by B. S. Belov, N. N. Kuzmina, L. G. Medyntseva, A. R. Babaeva, N. A. Shostak, E. V. Zhilyaev, S. E. Myasoedova, T. A. Raskina, S. P. Yakupova, V. N. Sorotskaya, E. N. Otteva

    Published 2016-10-01

    Diagnosis of acute rheumatic fever.

    Get full text
    Article

    Save to List
    Saved in:
  7. 7
    Use of tofacitinib in real clinical practice to treat patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs: Results of a multicenter observational study

    Use of tofacitinib in real clinical practice to treat patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs: Results of a m... by D. E. Karateev, D. E. Abdulganieva, A. R. Babaeva, A. A. Baranov, L. P. Evstigneeva, O. N. Ivanova, G. V. Lukina, E. L. Luchikhina, V. I. Mazurov, A. S. Misiyuk, O. V. Semagina, A. E. Sizikov, V. N. Sorotskaya

    Published 2016-09-01

    Tofacitinib (TOFA), a member of a new class of targeted synthetic disease-modifying antirheumatic drugs (DMARDs), is a promising medication for the treatment of rheumatoid arthritis (RA) and other immunoinflammatory diseases. The paper describes the Russian experi-ence with TOFA used to treat severe...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  8. 8
    The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational study

    The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic dru... by D. E. Karateev, D. E. Abdulganieva, A. R. Babaeva, A. A. Baranov, L. P. Evstigneeva, O. N. Ivanova, G. V. Lukina, E. L. Luchikhina, V. I. Mazurov, A. S. Misiyuk, O. V. Semagina, A. E. Sizikov, V. N. Sorotskaya

    Published 2017-03-01

    Tofacitinib (TOFA), a representative of a new class of targeted synthetic disease-modifying antirheumatic drugs (s-DMARD), is a promising drug for treating rheumatoid arthritis (RA) and other immune inflammatory diseases.Objective: to evaluate the efficiency and safety of therapy with TOFA in combin...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  9. 9
    Pharmacological treatment options for osteoarthritis: focus on symptomatic slow-acting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the International Expert Meeting

    Pharmacological treatment options for osteoarthritis: focus on symptomatic slow-acting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the... by A. M. Lila, L. I. Alekseeva, A. R. Babaeva, I. Z. Gaydukova, G. Gandolini, E. V. Zonova, R. Capelli, A. E. Karateev, S. S. Kopenkin, N. A. Martusevich, O. B. Nesmeyanova, E. N. Otteva, F. Rannuе, T. A. Raskina, M. L. Sukhareva, E. A. Taskina, N. V. Chichasova, S. P. Yakupova

    Published 2019-10-01

    The paper presents the results of the Osteoarthritis (OA) Expert Council held on September 8, 2019, which was attended by Russian and foreign specialists. The experts considered pharmacological treatment options for OA. The expert meeting resolution states that the treatment of patients with OA shou...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  10. 10
    ANALYSIS OF THE RESULTS OF TOFACITINIB THERAPY IN REAL CLINICAL PRACTICE ACCORDING TO THE ALL-RUSSIAN ARTHRITIS REGISTRY (OREL)

    ANALYSIS OF THE RESULTS OF TOFACITINIB THERAPY IN REAL CLINICAL PRACTICE ACCORDING TO THE ALL-RUSSIAN ARTHRITIS REGISTRY (OREL) by A. S. Avdeeva, A. S. Misiyuk, A. M. Satybaldyev, G. V. Lukina, V. N. Sorotskaya, E. V. Zhilyaev, A. R. Babaeva, A. A. Baranov, V. I. Mazurov, I. N. Shendrygin, T. S. Salnikova, L. A. Knyazeva, D. G. Krechikova, R. R. Samigullina, I. Z. Gaidukova, D. I. Abdulganieva, I. N. Kushnir, O. N. Anoshenkova, N. A. Lapkina, E. A. Koshkarova, A. M. Lila, E. L. Nasonov

    Published 2020-06-01

    Objective: to analyze the results of tofacitinib (TOFA) therapy in real clinical practice according to the All-Russian Arthritis Registry (OREL). Subjects and methods. The OREL Registry included 347 patients (286 (82%) women and 61 (18%) men) with rheumatoid arthritis (RA) who initiated TOFA therapy...

    Full description

    Get full text
    Article

    Save to List
    Saved in:

Search Tools: